Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 10/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6133987 | 0.91 | ADA (0.53) | ADA | |
| SCHEMBL6133658 | 0.85 | ADA (0.58) | ADAFFAR1FFAR4 | |
| SCHEMBL1385959 | 0.84 | ADA (0.51) | ADAFFAR1FFAR4KDM4AKDM5A | |
| SCHEMBL6133394 | 0.83 | MEN1 (0.31) | TRPM8MEN1ALDH1A1KMT2AFFAR1 | |
| Hydrochloric Acid SCHEMBL6133380 | 0.80 | ADA (0.53) | ADA | |
| SCHEMBL6134145 | 0.79 | ADA (0.58) | ADA | |
| Hydrochloric Acid SCHEMBL6133476 | 0.79 | ADA (0.59) | ADA | |
| SCHEMBL6133610 | 0.79 | ADA (0.59) | ADA | |
| SCHEMBL6170934 | 0.77 | ADA (0.66) | ADA | |
| SCHEMBL7575472 | 0.76 | ALDH1A1 (0.36) | TRPM8MEN1ALDH1A1KMT2AFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908940-B2 | Imidazole compounds and their use as adenosine deaminase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-21 | — | — | US | claimed |
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | claimed |
| US-6908940-B2 | Imidazole compounds and their use as adenosine deaminase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-21 | — | — | US | disclosed |
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ASTELLAS PHARMA INC. (JP) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097571-A1 | Imidazole compounds and their use as adenosine deaminase inhibitors | ADA, AMPD2, AMPD1 | ADA 1/4885TRPM8 3720/4885MEN1 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.